Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

PlanetiQ selected for NOAA’s Space-Based Environmental Monitoring IDIQ Achronix announces availability of high-performance JESD204C IP Core for Speedster7t FPGAs Paragraf launches PMF2002 GFET Platform and Enterprise Reader, expanding sensing portfolio PlanetiQ awarded $2.73 Million NOAA contract to provide GNSS-RO and TEC data NOAA NESDIS Commercial Data Program announces $6.4 million contract awards to support weather forecasting and space weather PlanetiQ completes major milestone for next-generation of GNOMES satellites
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Website powered by 100% renewable energy Privacy Policy